Cue Biopharma, Inc. (CUE) vs Entrada Therapeutics, Inc. (TRDA)

Cue Biopharma, Inc. and Entrada Therapeutics, Inc. are both Biotechnology companies. Cue Biopharma, Inc. and Entrada Therapeutics, Inc. are of similar size ($242.2M and $238.6M). Cue Biopharma, Inc. grew revenue faster over the last twelve months: 354.4% against −94.1%. Cue Biopharma, Inc. has the higher net margin (−435.8% vs −3,537.7%) and the higher return on invested capital (0.00% vs −1,060.2%). Across the 15 metrics below, Cue Biopharma, Inc. leads on 10 and Entrada Therapeutics, Inc. on 5.

Valuation

Metric CUE TRDA Biotechnology median
P/E n/m n/m 7.88
P/S 5.29 55.50 11.47
P/B 86.22 1.11 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 4.87 7.91 10.73
Earnings yield (86.03%) (64.29%) (28.84%)
Free cash flow yield (25.17%) (51.66%) (23.03%)

Profitability

Metric CUE TRDA Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (262.03%) (3,767.07%) 0.00%
Net margin (435.83%) (3,537.73%) 0.00%
Free cash flow margin (133.13%) (2,867.07%) 0.00%
Return on equity (1,603.48%) (54.09%) (57.72%)
Return on assets (459.60%) (44.35%) (49.22%)
Return on invested capital 0.00% (1,060.24%) 0.00%

Growth

Metric CUE TRDA Biotechnology median
Revenue growth (TTM) 354.37% (94.10%) 5.64%
EPS growth (last fiscal year) 61.11% (306.55%) —
Revenue growth, 5-year CAGR 54.16% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CUE TRDA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.25 10.89 4.73
Net debt to EBITDA 1.10 1.88 0.96

Dividend

Metric CUE TRDA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CUE TRDA Biotechnology median
Market cap 238.64m 242.19m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack